Anocca
- Company typePrivate
- Founded2014
- HeadquartersSödertälje, Sweden
- Headcount101–250
- GTM typeB2B
- OfferingServices
Anocca firmographics
Firmographics- Name
- Anocca
- Legal name
- Anocca AB (publ)
- Website
- https://anocca.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Anocca industry classification
Industry- Product category
- Cell therapy / TCR-T immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
Keywords
Where Anocca is headquartered
LocationHeadquarters
- HQ city
- Södertälje
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Anocca business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- TCR-T Cell Therapy Development and Manufacturing: Pre-revenue clinical-stage biotech developing proprietary TCR-T cell therapies. Revenue will be generated upon regulatory approval and commercialization of cell therapy products. The company manufactures personalized autologous TCR-T therapies for patients with specific cancer mutations and HLA genotypes.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Anocca product offering
Product offeringCore offering
Anocca develops and manufactures precision T-cell receptor-engineered T-cell (TCR-T) immunotherapies for hard-to-treat solid tumours, using proprietary engineered cell biology platforms (eAPC, eTPC, TORES, CSTE) and custom software (AnoccaOS) to identify cancer targets, discover TCRs, and produce personalised autologous cell therapies at an in-house GMP facility. Its lead candidate ANOC-001 (anti-KRAS G12V) is being evaluated in the VIDAR-1 Phase I/II umbrella trial for advanced pancreatic ductal adenocarcinoma, supported by a pipeline of 40+ preclinical TCR-T programmes against targets including KRAS, p53, RAC1, PRAME and the MAGE-A family.
Product overview
Anocca is a clinical-stage biopharmaceutical company developing a pipeline of precision T-cell receptor-engineered T cell (TCR-T) therapies for hard-to-treat solid tumours and other diseases. The core product offering is a systematic TCR-T discovery and manufacturing platform centred on AnoccaOS, comprising modular biotechnologies (eAPC, eTPC, TORES, CSTE) and integrated software that enables end-to-end capabilities from genetic target mapping to clinic-ready TCR-T cell therapy manufacture. The company operates a 5,000 m2 GMP-certified in-house manufacturing facility in Södertälje, Sweden, producing non-viral gene-edited autologous TCR-T therapies. The lead clinical product is ANOC-001 (part of the VIDAR-1 programme), targeting KRAS G12V mutations in pancreatic cancer, with additional pipeline candidates spanning KRAS, p53, RAC1, PRAME, MAGE-A family, NY-ESO-1, and HPV16-E7 targets across multiple HLA combinations from discovery through early clinical stages.
Differentiator
Problem solved
Functional benefit
Brands
- VIDAR-1: Phase I/II multi-product umbrella clinical trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC).
- ANOC-001
- AnoccaOS
- eAPC
- eTPC
- TORES
- CSTE
Products and services
- ANOC-001 (TCR-T therapy) ANOC-001 is Anocca's lead product candidate — a T-cell receptor-modified T-cell therapy (TCR-T) targeting mutant KRAS G12V in advanced pancreatic ductal adenocarcinoma (PDAC). It is the first non-viral gene-edited TCR-T therapy to enter clinical evaluation in Europe and is being assessed within the VIDAR-1 clinical programme for patients with matching HLA genotypes.
- VIDAR-1 Clinical Programme VIDAR-1 is a Phase I/II multi-product umbrella clinical trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma. The programme is designed to investigate up to 20 patients per product across multiple TCR-T product candidates targeting distinct KRAS mutations and HLA combinations, conducted at eight sites across Sweden, Denmark, Germany and the Netherlands.
- TCR-T Oncology Pipeline Anocca's primary pipeline of precision T-cell receptor engineered T-cell (TCR-T) therapies for solid tumours, comprising 40+ preclinical and clinical assets against KRAS driver mutations (G12V, G12D), dysregulated genes (p53, RAC1), cancer-testis antigens (PRAME, MAGE-A4, MAGE-A3, MAGE-A1, MAGE-A10, NY-ESO-1) and onco-viral targets (HPV16-E7), spanning discovery through early clinical stages.
- GMP Manufacturing Facility (5,000 m², Södertälje) A 5,000 m² GMP-certified in-house cell therapy manufacturing facility in Södertälje, Sweden — the largest cell-therapy manufacturing facility in the Nordics — with internal process development and quality teams producing clinical supply of autologous TCR-T cell therapies using non-viral gene-editing technology.
- AnoccaOS Software Ecosystem AnoccaOS is Anocca's proprietary integrated software ecosystem built to model the scope and complexity of T-cell biology. It provides storage and organisation of biological entities and data, custom data analysis pipelines, comprehensive visualisation tools, and automation of workflows across the platform.
Quantifiable outcome
- Broadest pipeline of TCR-T oncology cell therapy treatments with 40+ preclinical assets and programs across Discovery (19), Lead Optimization (12), IND Enabling (11), and Early Clinical (1) stages
- +2 more outcomes
Companies that use Anocca
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Anocca technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature10 records
Anocca partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, unclear and minor.
- Shinobi TherapeuticscoreStrategic partnership to co-develop immune-evasive allogeneic TCR-engineered iPS-T cell therapies (TCR-iPS-T) for solid tumors. Anocca provides novel candidate TCRs discovered and validated by its platform while Shinobi contributes its proprietary Katana immune evasive iPS-T cell platform. Joint program aims to produce TCR engineered CD8 αβiPS-T cells against validated cancer targets for pre-clinical proof of concept and future off-the-shelf treatments.
- EmendoBio Inc.coreNon-exclusive licensing agreement for EmendoBio's novel OMNI-A4 nuclease to accelerate manufacture and development of Anocca's deep pipeline of TCR-T cell therapies. The next-generation gene editing system provides precision and efficiency needed to scale out production of growing libraries of TCR-T products in a high-precision manufacturing process.
- Janssen Research & Development, LLCunclearHealthcare partner collaboration for development activities.
- SciLifeLabminorStrategic collaboration with national molecular bioscience research center in Sweden.
- Karolinska InstitutetcoreAcademic research partnership with leading Swedish medical university including Phase I Clinical Trials Unit and Center for Apheresis and Stem Cell Handling at Karolinska University Hospital for clinical trial operations.
- Phase I Clinical Trials Unit, Karolinska University HospitalcoreClinical site partnership for VIDAR-1 Phase I/II clinical trial conducting patient enrollment and treatment administration.
- Center for Apheresis and Stem Cell Handling, Karolinska University HospitalcoreClinical site partnership providing apheresis services for collection of patient T-cells for autologous TCR-T manufacturing.
- R T Cure (Rheuma Tolerance for Cure)minorResearch collaboration for autoimmune disease applications of T-cell therapy platform.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Anocca competitors and assessment
Company assessmentDirect peers
- Adaptimmune Therapeutics: Clinical-stage TCR-T cell therapy company developing SPEAR T-cells for solid tumors, with FDA-approved afami-cel for synovial sarcoma. Most directly comparable to Anocca given shared TCR-T focus on solid tumor targets including MAGE-A4.
- Crispr Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based cell therapies including allogeneic CAR-T products. Directly comparable to Anocca's CRISPR-Cas gene editing approach to TCR-T manufacturing.
- Cellectis: Clinical-stage gene editing company developing allogeneic CAR-T and TCR-T cell therapies using TALEN gene editing. Comparable technology platform to Anocca with overlapping TCR-T focus.
Broad incumbents
- Iovance Biotherapeutics: Leading commercial-stage cell therapy company with FDA-approved lifileucel for solid tumors (TIL therapy). Comparable as a cell therapy company targeting solid tumors but uses tumor-infiltrating lymphocytes rather than engineered TCR-T.
- Allogene Therapeutics: Clinical-stage allogeneic CAR-T cell therapy company developing off-the-shelf cell therapies. Comparable as cell therapy platform company though focused on allogeneic rather than autologous TCR-T approaches.
Emerging players
- Precision BioSciences: Clinical-stage gene editing company using ARCUS meganuclease platform for cell therapy and in vivo gene editing. Comparable as gene-edited cell therapy developer with technology overlap in TCR engineering.
- Editas Medicine: Clinical-stage CRISPR gene editing company developing gene-edited cell therapies including allogeneic CAR-T. Comparable technology platform focus though earlier stage in TCR-T specifically.
- Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company developing both in vivo and ex vivo cell therapies. Comparable gene editing platform technology relevant to Anocca's TCR engineering capabilities.
- Caribou Biosciences: Clinical-stage allogeneic CAR-T cell therapy company using CRISPR-based gene editing. Comparable as a gene-edited cell therapy platform though focused on allogeneic rather than autologous approaches.
- Triumvira Immunologics: Clinical-stage cell therapy company developing TAC-T cell therapies targeting solid tumors. Comparable as an emerging cell therapy platform targeting solid tumor indications similar to Anocca's focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Anocca social profiles
Digital presenceAnocca compliance and trust
Trust signalCompliance1 record
Anocca financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anocca leadership team
Management profileNumber of profiles
Profiles19 records
Anocca funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anocca M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anocca
What does Anocca do?
Anocca develops and manufactures precision T-cell receptor-engineered T-cell (TCR-T) immunotherapies for hard-to-treat solid tumours, using proprietary engineered cell biology platforms (eAPC, eTPC, TORES, CSTE) and custom software (AnoccaOS) to identify cancer targets, discover TCRs, and produce personalised autologous cell therapies at an in-house GMP facility. Its lead candidate ANOC-001 (anti-KRAS G12V) is being evaluated in the VIDAR-1 Phase I/II umbrella trial for advanced pancreatic ductal adenocarcinoma, supported by a pipeline of 40+ preclinical TCR-T programmes against targets including KRAS, p53, RAC1, PRAME and the MAGE-A family.
Is Anocca a public or private company?
Anocca is a private company. It is classified as venture growth investor backed and is currently operating.
When was Anocca founded?
Anocca was founded in 2014. It employs 101 to 250 people.
Where is Anocca based?
Anocca is headquartered in Södertälje, Sweden, in the Europe region.
How does Anocca make money?
One revenue line is on record: TCR-T Cell Therapy Development and Manufacturing.
Who are Anocca's main competitors?
Direct peers on record are Adaptimmune Therapeutics, Crispr Therapeutics and Cellectis. Broad incumbents are Iovance Biotherapeutics and Allogene Therapeutics. Emerging players are Precision BioSciences, Editas Medicine, Intellia Therapeutics, Caribou Biosciences and Triumvira Immunologics.
Does Anocca have an API?
No public API is recorded for Anocca.
What industry is Anocca in?
Anocca's product category is Cell therapy / TCR-T immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.